Eisai plots new drug applications in US, Europe and China after Lenvima scores in head-to-head liver cancer study
Eisai says that its cancer drug Lenvima (lenvatinib) hit the primary endpoint in a Phase III study for first-line use against liver cancer, proving …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
